Wells Fargo & Company Logic Bio Therapeutics, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.67 $1 - $3	5 Added 0.41%	1,231 $0
Q2 2022 Aug 12, 2022	BUY	$0.35 - $0.74 $3 - $7	10 Added 0.82%	1,226 $0
Q1 2022 May 16, 2022	BUY	$0.61 - $2.49 $1 - $7	3 Added 0.25%	1,216 $1,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $5.09 $2,356 - $3,115	612 Added 101.83%	1,213 $6,000
Q2 2021 Aug 16, 2021	SELL	$4.03 - $7.57 $406,155 - $762,927	-100,783 Reduced 99.41%	601 $2,000
Q1 2021 May 13, 2021	BUY	$6.8 - $9.16 $566,440 - $763,028	83,300 Added 460.63%	101,384 $739,000
Q4 2020 Feb 09, 2021	BUY	$5.29 - $9.1 $30,131 - $51,833	5,696 Added 45.98%	18,084 $138,000
Q3 2020 Nov 05, 2020	SELL	$5.41 - $9.45 $17,068 - $29,814	-3,155 Reduced 20.3%	12,388 $112,000
Q2 2020 Aug 13, 2020	BUY	$4.25 - $8.46 $25,219 - $50,201	5,934 Added 61.75%	15,543 $131,000
Q1 2020 May 14, 2020	BUY	$4.06 - $11.0 $39,012 - $105,699	9,609 New	9,609 $47,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.